Beam’s base-editing therapy extends fasting tolerance in early GSDIa trial

Early data from six patients suggest a single dose of BEAM-301 may improve fasting tolerance and reduce starch requirements in glycogen storage disease type Ia. Beam Therapeutics is preparing to present early human data from its Phase I/II study of…















